Aurora Cannabis Inc. · TSX:ACB
Aurora Cannabis — Q2 2025 Earnings Presentation
18 slides from Aurora Cannabis's earnings presentation, Nov 6, 2024
Slide 1: Investor Presentation FY25 Q2
INV ES TOR P RE S E NT A TIO N FY25 Q2 November 2024
Slide 2: Disclaimer
Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information contained in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact may be deemed
Slide 3: Diversified Global Business Model
Diversified Global Business Model Focus on Defensive, Stable, High Margin Segments International Canadian Medical Plant Propagation Adult Recreational Science & Innovation Medical #1 Canadian Medical Controlling interest in Bevo, one of Ability to deliver products Delivering a continuous stream shar
Slide 4: Leading Global Cannabis Platform
Leading Global Cannabis Platform • Global medical cannabis net revenue(1) reached a record $61.3m in Q2, up 41% compared to the prior year period. • Increased revenue primarily attributable to increasing sales in Canada, Germany, Australia, Poland and the UK. • Adjusted gross margins(1) for medical
Slide 5: Leadership in Key Global Cannabis Markets
Leadership in Key Global Cannabis Markets UNITED KINGDOM: 68m population • Solid market position through relationships with POLAND: 40m population key distributors and supply of Channel Islands; a high-growth market due to less rigid prescriber • Rapidly growing medical market regulations • Aurora c
Slide 6: European Medical Leadership
European Medical Leadership Aurora is a leader in the German, Polish and UK markets due to a consistent supply of high-quality EU GMP manufactured products. Aurora Product Range 7 . Consistent Revenue Stream and Margin Leader ae ante | + Aurora Europe posted another record quarter in Q2 thanks to hi
Slide 7: Australia & New Zealand Market Leadership
Australia & New Zealand Market Leadership Following the acquisition of MedReleaf Australia, the # 2 player in the market, Aurora has expanded its medical product portfolio, to meet the growing needs of the patients in Australia and New Zealand Consistent Revenue Stream and Margin Leader • #2 Market
Slide 8: Latest Product Launches Australia & New Zealand
Latest Product Launches Australia & New Zealand This year, Aurora launched a full portfolio of products and formats across market segments. In Q2, Aurora rounded out its portfolio by launching nine new edible SKUs under the Aurora and IndiMed brands and re-introducing Pink Kush to the market under I
Slide 9: Canadian Medical Leadership
Canadian Medical Leadership Aurora is leading the market with four owned brands and a wide variety of marketplace offerings. Aurora partnered with Vectura Fertin Pharma to launch LUO TM, an innovative CBD lozenge Consistent Revenue Stream and Margin Leader • #1 Canadian Medical Share by revenue; ~3%
Slide 10: Latest Canadian Medical Innovations
Latest Canadian Medical Innovations Dried Flower Lotions & Topicals Oils & Capsules Edibles & Beverages Vapes & Concentrates • Medreleaf Noculus • Turmeric and Arnica • Morning, Noon & Night • Luo TM Vanilla mint lozenges • Tastys Blue Raspberry • WMMC Kootna Kush relief balm CBD Oral Spray Vape • W
Slide 11: A Compelling Portfolio of Adult Recreational Brands
A Compelling Portfolio of Adult Recreational Brands Core Alternative Premium Super Premium Maximum Flavour, Maximum Potency, High-THC edibles for the Proprietary genetics with unique aromas Exceptional true-to-cultivar, craft offerings. Brand Promise Maximum Value modern-day consumer in a range of s
Slide 12: Sales and Marketing Support
Sales and Marketing Support Ongoing national campaign focused on maximizing brand and product Innovation will be communicated to retailers via national e-mail and in- awareness, further enhancing purchase consideration for Tasty's Vapes. store pitches. They will be supported by a full suite of digit
Slide 13: Plant Propagation Overview
Plant Propagation Overview • Aurora holds a controlling interest in Bevo Farms, an industry leader in plant propagation and one of the largest suppliers of propagated vegetables and ornamental plants in North America. • Bevo is cash flow positive on an annualized basis and contributed strong revenue
Slide 14: Science & Innovation Program
Science & Innovation Program A state-of-the-art breeding facility in Vancouver Island’s Comox Valley: • Built specifically to find the next big genetics: high yielding, high cannabinoid strains with unique terpene flavours and distinctive experiences • Delivered 23 new proprietary cultivars, grown a
Slide 15: Key Takeaways
Key Takeaways Opening the Largest global medical cannabis company in nationally legal markets World to Diversified and growing footprint in high-margin medical cannabis markets across the globe Cannabis Consistent sequential and year-over-year revenue growth, including record global medical re
Slide 16: Senior Management Team
Senior Management Team Miguel Martin Executive Chairman & CEO Miguel’s career spans nearly 30 years in consumer- packaged goods, covering various regulated categories and fast-moving markets. Miguel is the former CEO & President of Reliva. Simona King Nathalie Clark Alex Miller Chief Financial Offic
Slide 17: Board of Directors
Board of Directors Miguel Martin Executive Chairman & CEO Miguel’s career spans nearly 30 years in consumer- packaged goods, covering various regulated categories and fast-moving markets. Miguel is the former CEO & President of Reliva. Norma Beauchamp Theresa Firestone Ronald Funk Director Director
Slide 18: Investor Presentation
INVESTOR PRESENTATION Email: aurora@icrinc.com Website: auroramj.com/investors